Results from the PCCTC-managed Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line mCRPC with DNA Repair Defects (BRCAAway) Study Published in Clinical Cancer Research

Written By Kristofer Prepelica, PhD

The data from this trial supports an advantage of upfront combination therapy with ARP-I + PARP-I versus either single-agent alone in patients with metastatic castration resistant prostate cancer and qualifying HRR mutations.

Kristofer Prepelica, PhD
Previous

The Prostate Cancer Clinical Trials Consortium (PCCTC) Receives Gift from Friends and Family Against Prostate Cancer
Next

American Cancer Society, Trial Library, and the PCCTC Collaborate to Support Recruitment of Black Patients for Clinical Trials